Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Pirtobrutinib vs nemtabrutinib in CLL

Catherine Coombs • 29 Sep 2022
SOHO 2022
Chronic Lymphocytic Leukemia Leukemia Nemtabrutinib Pirtobrutinib

Catherine Coombs, MD, University of North Carolina, Chapel Hill, NC, gives an overview of the main differences between pirtobrutinib and nemtabrutinib in the treatment of chronic lymphocytic leukemia (CLL) and B-cell malignancies. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Catherine Coombs

1:01
Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trial
Catherine Coombs • 8 Dec 2023
1:05
BTK degraders in the treatment of CLL
Catherine Coombs • 8 Dec 2023
1:30
The use of pirtobrutinib in Richter's transformation: data from the BRUIN trial
Catherine Coombs • 8 Dec 2023
1:32
Novel BTKi strategies in indolent B-cell malignancies: pirtobrutinib for FL and MZL
Catherine Coombs • 8 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals